glp 1 fda compounding is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified FDA proposes a new GLP-1

Blood pressure normalizes, allowing medication reduction or elimination

As a synthetic analog of its endogenous exendin-4, compared with exendin-4, LIXI deleted one proline and added six lysine residues, which increased its binding affinity with the GLP-1R by four times and increased its circulating half-life ( A prospective clinical study from Spain found that besides controlling blood glucose (fasting blood glucose and glycosylated hemoglobin), LIXI can also improve blood lipids, especially total cholesterol and triglyceride ( In clinical studies, LIXI has shown the benefits of weight loss, which is well tolerated by patients and can meet the needs of overweight patients for weight control

So I've also started to be more open about sharing my journey and advocating for women in science

Which one do we choose

Ascletis reported enhanced fat loss with ASC47 in semaglutide combo studies